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Background: S-allyl mercaptocysteine (SAMC), a water-soluble component derived from garlic, has been found to
exert multi-antitumor activities. This study was to investigate the responsible molecular mechanisms of SAMC in
human breast cancer cell lines.
Methods: Sulforhodamine B assay was used to determine cell viability, flow cytometry was applied for the analysis
of cell cycle and cell apoptosis, the change of protein was detected by Western blot.
Results: It was found that SAMC exhibited an effective cell growth inhibition of human breast cancer cell lines
MCF-7 (ER positive) and MDA-MB-231 (ER negative) in a dose- and time-dependent manner by inducing cell cycle
arrested in G0/G1 phase, the block of cell cycle was associated with the up-regulation of p53 and p21. Furthermore,
the SAMC-mediated cell cycle arrest was accompanied with promotion of apoptosis, as indicated by the changes in
the nuclear morphology and expressions of apoptosis-related proteins. SAMC clearly triggered the mitochondrial
apoptotic pathway as indicated by activation of Bax, decreased expression of Bcl-2 and Bcl-XL, and subsequent
activation of caspase-9 and caspase-3.
Conclusion: These results highlight the value of a continued investigation into the use of SAMC as a potential
antitumor candidate for breast cancer.
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Breast cancer is the top cancer in women both in the de-
veloped and developing world. The incidence of breast
cancer has been increasing in the developing world and
it has been the second leading cause of cancer death
worldwide [1]. Each year there are more than 230,000
new cases and more than 30,000 women died from this
disease [2]. Breast cancer is a heterogeneous disease with
distinct clinical behaviors and molecular properties; in
particular estrogen receptor (ER) positive and ER nega-
tive cancers are the two most distinct subtypes [3]. The
treatment of breast cancer depends on various genetic,
molecular and histological factors. In general, ER posi-
tive cells exhibit a higher proliferative capacity and dis-
tinct drug response than ER negative cells [4,5]. However,
ER negative cancer cells are generally more sensitive to
chemotherapy, but associated with poor clinical outcomes* Correspondence: guimeilin@sdu.edu.cn; uszxzhao@gmail.com
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unless otherwise stated.[6,7]. In clinic, the radiation therapy following breast-
conserving surgery is recommended for early-stage breast
cancers [8,9]. Unfortunately, the majority of patients suffer
from a high proportion of drug resistance and die of dis-
seminated metastatic disease [8]. As a result, it becomes
primary importance to search for more efficient and less
toxic adjuvant therapeutic strategies that lead to better
drug-free and overall survival.
The use of new therapeutic approaches based on
plant-derived natural products for the prevention and
treatment of cancer has gained a momentum in the past
decades. Garlic (Allium sativum), a member of the lily
family, is characterized by many sulfur-containing com-
pounds, which make a main contribution to its bioactiv-
ities. A large amount of data indicates that garlic and its
organosulfur compounds have anticarcinogenic activ-
ities. The use of garlic as anticancer dietary supplements
had been reviewed by Fleischauer and Arab [10]. Indi-
vidual organosulfur compounds in garlic have been stud-
ied in an attempt to identify the mechanisms of theirLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
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compounds such as diallyl sulfide (DAS), diallyl disulfide
(DADS), and diallyl trisulfide (DATS) [11-15]. For the
water-soluble constituents such as S-allylcysteine (SAC)
and S-allyl mercaptocysteine (SAMC), limited experimen-
tal studies also suggested that both water-soluble com-
pounds can suppress cancer risk and alter the biological
behaviors of various human tumors such as breast, pros-
tate, bladder, colorectal and gastric cancers [16-21].
Li et al. examined the modulatory effect of SAC and
SAMC on growth and glutathione cycle in two human
cell lines MCF-7 and MCF-7(ras) [21]. It was found that
SAC and SAMC produced an anti-proliferative response
under both anchorage dependent and independent con-
ditions as well as an alteration in glutathione level with-
out significant concurrent changes in the glutathione
metabolizing enzymes. Sigounas et al. has previously re-
ported on the anti-breast cancer effects of SAMC and
concluded that SAMC inhibited cell proliferation and re-
duced the viability of the breast cell line MCF-7 [19].
However, the mechanisms of inhibition effects in human
breast cancer cell lines have not been clearly demon-
strated. In this work, the antiproliferative effects of
SAMC on both ER-positive (MCF-7) and ER-negative
(MDA-MB-231) human breast cancer cell lines were in-
vestigated. The molecular mechanisms studied in this
work include the assessment of the cell viability, cell
migration, cell cycle distribution, and apoptosis which
are mainly related to the expressions of tumor sup-
pressor p53, p21, induced transcription of apoptosis-
responsible genes such as Bax and Bcl-2 and activation
of the caspase cascade. Our study revealed that SAMC
inhibited cell proliferation by delaying the cell cycle at
G0/G1 phase and triggered cell apoptosis through the




SAMC was synthesized and purified in our laboratory
with a modified procedure as previously reported [22,23].
A stock solution of SAMC (10 mM) was freshly prepared
in PBS. Propidium iodide (PI), 4′,6-diamidino-2-phenylin-
dole (DAPI), sulforhodamine B (SRB) were purchased
from Sigma-Aldrich (St. Louis, Missouri, USA). Caspase-
3/7, −8 and −9 activity, JC-1 and BCA protein assay kits
were provided by Beyotime Institute of Biotechnology
(Haimen, Jiangsu, China). Primary antibodies to p53, Bax,
Bcl-2 and FADD (fas-associated protein with death do-
main) were obtained from Abcam (Cambridge, United
Kingdom). The antibodies to cyclin D1, cyclin E1, cyclin
A2, PCNA (Proliferating cell nuclear antigen), caspase-7,
cytochrome c and Bcl-XL were purchased from Epitomics,
Inc. (Burlingame, CA). The antibodies to p21, E-cadherinand PARP (Poly (ADP-ribose) polymerase) were acquired
from Merck Millipore (Darmstadt, Germany).
Cell lines and cell culture
Human breast cancer cells MCF-7 and MDA-MB-231
were purchased from China Cell Bank (Shanghai, China).
All cell lines were cultured in Dulbecco’s modified Eagle’s
Medium with 10% fetal bovine serum, 100 U/mL of peni-
cillin and 100 μg/mL of streptomycin and maintained in a
humidified incubator of 5% CO2 at 37°C. When the grow-
ing cells reached approximately 70–90% confluence, they
were treated with SAMC. The vehicle without SAMC was
served as a control.
Cell viability assay
The cytotoxicity of SAMC on human breast cancer cells
MCF-7 and MDA-MB-231 was measured by SRB method
[24]. The cells were seeded into 96-well plates for 24 h;
then treated with SAMC for 24, 48 and 72 h. The treated
cells were then fixed with 10% TCA for 1 h at 4°C, the 96-
well plates were washed five times with distilled water and
allowed to dry in the air. Each well was added with 100 μl
of sulphorhodamine (SRB) solution and the staining was
completed at room temperature for 15 min. The SRB stain
solution was removed by washing the plates quickly with
1% (v/v) acetic acid five times, and the plates were dried in
the air. The dried materials in each well were solubilized
by adding 200 μl of 10 mM unbuffered Tris Base
(pH 10.5). The cell viability was detected by measuring
the absorbance at 540 nm on a plate reader (Safire2,
TECAN, France). All experiments were repeated at least
three times.
DAPI staining
The human breast cancer cells MCF-7 and MDA-MB-
231 were grown on 24-well plates for 24 h prior to the
SAMC treatment and then treated with SAMC for 24 h.
The treated cells were washed with PBS and fixed with
cold methanol/acetone (1:1, store at −20°C) for 5 min at
room temperature, the solution was removed and
washed with PBS, and then incubated with the DAPI so-
lution for 10 min at room temperature. Fluorescence im-
ages were captured using an Olympus model IX71
fluorescence microscope (Tokyo, Japan).
Apoptosis analysis by annexin V and propidium iodide
staining
The seeded human breast cancer cells MCF-7 and
MDA-MB-231 in 6 well-plates were either treated with
PBS or SAMC for 24 h. Detached and adherent cells
were harvested and washed with PBS, then re-suspended
in the binding buffer and stained with annexin V and
propidium iodide (PI) according to the manufacturer’s
instructions (Invitrogen, Carlsbad, USA). Apoptotic cells
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cytometer (Brea, CA, USA).
Cell cycle analysis by flow cytometry
The human breast cancer cells MCF-7 and MDA-MB-
231 were seeded in 6-well plates and grown overnight to
achieve 80% confluence. After treatment with PBS or
SAMC, all the cells were selected and washed with cold
PBS, then fixed with iced 70% ethanol at 4°C overnight,
centrifuged and washed with PBS. The washed cells were
re-suspended and incubated with 0.5 mL of PBS con-
taining 100 μg/mL RNase for 30 min at 37°C, and then
incubated with 50 μg/mL PI for 30 min in the dark at 4°C.
The cellular DNA content was analyzed by a Beckman
Coulter model FC500 flow cytometer (Brea, CA, USA).
Data were analyzed by using MODFIT and CELLQUEST
software (Verity Software House, Topsham, Maine, USA).
Wound closure assay
The breast cancer cells were seeded in 6-well plates and
cultured until 90%-95% confluent. Three similar sized
wounds were generated by scratching a gap using a ster-
ile yellow pipette tip. Wounded monolayer cells were
washed by PBS to clear cell debris and then incubated in
a culture medium with or without SAMC. Images were
captured under 40× magnifications every 8–12 hours
using a phase-contrast microscope until the completed
closure of the wound was observed in the vehicle-
treated control.
Assay for caspase-3/7, −8 and −9 activities
The assay for caspase-3/7, −8 and −9 activities was
based on the ability of the active enzyme to cleave the
chromophore from the enzyme substrates Ac-DEVD-
pNA for caspase-3/7, Ac-LEHD-pNA for caspase-9, and
Ac-IETD-pNA for caspase-8. Caspase activities were
measured according to the manufacturer’s instructions.
Levels of the released pNA were measured at 405 nm on
a TECAN model Infinite M200 plate reader (Männedorf,
Switzerland). All experiments were repeated at least
three times.
Analysis of mitochondrial membrane potential (ΔΨm)
The mitochondrial membrane potentials (ΔΨm) were ana-
lyzed by using a JC-1 assay kit according to the manufac-
turer’s instructions. Cells treated with carbonyl cyanide
m-chlorophenylhydrazone (CCCP) were served as a posi-
tive control. Fluorescent intensity was measured by a
Beckman Coulter model FC 500 flow cytometer (Brea,
CA, USA).
Western blot analysis
The whole-cell lysates were prepared by re-suspending
cell pellets in the RIPA buffer. Equal amounts of proteinswere loaded and separated by electrophoresis using SDS-
PAGE (12%) and electro-transferred onto the polyvinyli-
dene difluoride (PVDF) membrane. After blocking with
5% non-fat milk for 1 h at room temperature, the mem-
branes were incubated with specific antibodies at 4°C
overnight under slow migration. The antibodies to p53,
p21, Bax, Bcl-2, Bcl-XL, FADD, PCNA, cyclin E1, cylcin
D1, cyclin A2, caspase 7, cytochrome C, E-cadherin and
PARP were used for corresponding protein development.
Glyceraldehyde-3-phosphatedehydrogenase (GAPDH) was
used as a housekeeping gene. Proteins of interest were vi-
sualized by an enhanced chemiluminescence detection
system (Merck Millipore, Darmstadt, Germany) and the
images were captured by Alphalmager HP system (Cell
Biosciences, Inc., Santa Clara, CA, USA).
Statistical analysis
Data from viability, cell cycle analysis and enzyme activ-
ity were obtained from experiments performed at least
three times independently. Images were edited by Adobe
Photoshop and figures were created by Origin 8.5. The
student’s t-test was used to determine statistical differ-
ences between treated groups and controls, and P < 0.05
was considered statistically significant. The values were
presented as mean ± SD. The significance level was cal-
culated using one-way analysis of variance to assess the
differences between experimental groups.
Results
Effects of SAMC on proliferation and cell cycle arrest of
breast cancer cells
The in-vitro anti-proliferation effects of SAMC on hu-
man breast cancer and were investigated on cancer cell
lines ER-positive MCF-7 and ER-negative MBA-MD-
231. As show in Figure 1A, SAMC significantly inhibited
proliferation of breast cancer cells MCF-7 and MBA-
MD-231 in a time- and dose- dependent manner. The
IC50 value of SAMC was 148 μM for MCF-7 cells and
207 μM for MDA-MB-231 cells at 72 h.
The unrestrained cell proliferation leads to the gener-
ation of tumors, therefore, induction of cell cycle arrest
has been appreciated as a target for the management of
cancer [25,26]. The DNA contents of MCF-7 and MDA-
MB-231 cells after being treated with SAMC for 24 h
were examined to confirm the proliferation inhibitory ef-
fects of SAMC on human breast cancer cells via the
induction of cell cycle arrest. As show in Figure 1B,
SAMC treatment induced a dose-dependent accumula-
tion of cells in the G0/G1 phase and a corresponding de-
crease in S phase fraction in both breast cancer cell lines
MCF-7 and MDA-MB-231. The accumulation of sub-G1
phase cells, a hallmark of apoptosis, was noted at high
concentrations of 400 and 600 μM (Figure 1C). These
results suggest that the proliferation inhibition of breast
Figure 1 (See legend on next page.)
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Figure 1 The inhibitory effects and cell cycle progression of SAMC on human breast cancer cells. The experiments were performed in
triplicate and data are presented as mean ± S.D. of three independent experiments, *p < 0.05 when compared with control group. (A) Cytotoxic
effects of SAMC on breast cancer cells for 24, 48 and 72 h measured by the SRB assay. (B) Cells were treated with SAMC (0–600 μM) for 24 h. For
cell cycle analysis, cells were fixed, stained with PI and analyzed by flow cytometry. Quantitative analysis of percentage gated cells at G0/G1, S
and G2/M phases were shown. All values were expressed as mean ± S.D. (C) Cell cycle analysis by flow cytometry, a hallmark of apoptosis was
noted at high concentration of 400 and 600 μM.
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was through cell-cycle arrest in the G0/G1 phase.
The intracellular localization of different cell cycle-
regulating proteins also contributes to a correct cell
cycle progression. Our Western blot assay results further
demonstrate that SAMC decreased the expression of
cyclin D1, cyclin E1 and cyclin A2, molecular makers of
associated with the G1/S phase, in a dose-dependent
manner in MCF-7 and MDA-MB-231 cells (Figure 2A).
The p53 was the first tumor suppressor gene to be iden-
tified and believed to play an important role in regulat-
ing of cell cycle checkpoints [27]. The changes of p53
and its downstream target cyclin-dependent kinase in-
hibitor p21 were examined to determine their regulatory
effects. As shown in Figure 2, induction of p53 was no-
ticeable with increased concentrations of SAMC, andFigure 2 The effects of SAMC on cell cycle by western blot analysis. T
antibody served as a loading control. The experiments were performed in
compared with control group.elevated p21 in SAMC-treated cells was correspondingly
increased in a dose-dependent manner. Proliferating cell
nuclear antigen (PCNA), a member of the so called
DNA sliding clamp family, plays a coordinating role for
numerous proteins involved in many processes involving
DNA, such as DAN replication, DNA repair and cell
cycle control [28-30]. The expression of PCNA was de-
creased following the treatment of MCF-7 and MDA-
MB-231 cells with SAMC (Figure 2B). Thus, these
results indicate that SAMC affected G0/G1 cell cycle
checkpoints and caused a block of cell cycle progression.
Effect of SAMC on breast cancer cell migration
The metastatic stage was believed to be the main obstacle
in the treatment of breast cancer, where breast cancer
cell migration could be one of important characteristicshe cyclins, p53, p21 and PCNA were investigated with the GAPDH
triplicate and all values were expressed as mean ± S.D., *p < 0.05 when
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tions of human breast cancer cell lines MCF-7 and
MDA-MB-231 after the treatment with SAMC were ex-
amined by using the wound closure assay. As shown in
Figure 3A, the gap of wounds was gradually filled with
migrating cells even almost completely closed (indicated
by solid arrow) at 48 h after wound introduction,
whereas the gap was still widely open (indicated by dot-
ted arrow) in the controls. This inhibitory effect on cell
migration was not the result of cell growth inhibition in-
duced by these compounds as there was no significant
difference in cell growth rate between the treated and con-
trol cells up to 48 hours post exposure time. Furthermore,Figure 3 The inhibitory effects of SAMC on cell migration. (A) Differen
(B) Western blot analysis of E-cadehrin with GAPDH antibody served as a lo
values are expressed as mean ± S.D., *p < 0.05 when compared with controconsidering the aberrant expression of E-cadherin is a
common event in primary invasive ductal carcinomas that
progress to develop distant metastases, we investigated
the role of SAMC on regulating E-cadherin and found
that SAMC was able to improving E-cadherin expression
by western blot assay as shown in Figure 3B. These results
indicate that SAMC treatment led to suppression of breast
cancer cell migration, and may also be effective agents for
the treatment of invasive cancers.
SAMC induced apoptosis in breast cancer cells
DAPI staining was used to analyze the morphological
changes of cells treated with SAMC. The condensed andtial cell migration rates were examined using a wound closure assay.
ading control. The experiments were performed in triplicate and
l group.
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death was observed as illustrated in Figure 4A. Quantifi-
cation of the percentage of apoptosis induced by SAMC
on breast cancer cells was performed by annexin V/PI
staining and analyzed by a flow cytometer. As show in
Figure 4B, SAMC treatment caused significant increases
in the fraction of apoptotic cells in a dose-dependent
manner, the percentage of apoptotic cells was increased
from 1.1% to 45.5% in MCF-7 cells treated with 600 μM
of SAMC (upper panel), and from 0.9% to 40% in MDA-
MB-231 cells under same conditions (lower panel).
Caspase activation represents the irreversible or ex-
ecution stage of apoptosis [32,33]. The involvement ofFigure 4 SAMC induced apoptosis in breast cancer cells. (A) Fluoresce
DAPI staining. (B) Flow cytometric analysis of SAMC induced apoptosis in MC
were performed in triplicate and values are expressed as mean ± S.D., *p < 0.0caspases in apoptosis induction of SAMC was evaluated.
The activities of caspase-3/7, caspase-9 and caspase-8
were also examined as shown in Figure 5A,B and C, re-
spectively. It was found that caspase-3/7, caspase-9 and
caspase-8 were all activated significantly when the breast
cancer cell lines MCF-7 and MDA-MB-231 were treated
with SAMC. These results indicate that both death re-
ceptor (extrinsic) and mitochondrial (intrinsic) pathways
were involved in SAMC induced apoptosis. The Western
blot analysis demonstrated that SAMC dramatically acti-
vated caspase-7 by increasing the cleaved caspase-7
level, which in turn led to the cleaved PARP in both
MCF-7 and MDA-MB-231 cells. In addition, increasednt micrographs of SAMC treated and untreated breast cancer cells after
F-7 and MDA-MB-231. (C) Statistical analysis of apoptosis. The experiments
5 when compared with control group.
Figure 5 Effects of SAMC on the activities of caspases, FADD and PARP. Effects of SAMC on the activities of caspase-3/7, caspase-9 and
caspase-8 in human breast cancer cell lines MCF-7 and MDA-MB-231 are shown in (A), (B) and (C), respectively. (D) The levels of caspase-7, PARP
and FADD were measured by Western blot analysis. MCF-7 and MDA-MB-231 cells were exposed to various concentrations of SAMC. The values
of optical density (OD) at 405 nm were determined in triplicate and all values are presented as mean ± S.D. of three independent experiments,
*p < 0.05 vs. control cells.
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partially indicating that SAMC-triggered apoptosis was
caspase-dependent.
Mitochondrial dysfunction and regulation of expression
of Bcl-2 family proteins caused by SAMC
Mitochondrial membrane potentials regulate mitochon-
drial permeability, which plays an important role in
triggering apoptotic pathways. The effect of SAMC onmitochondrial membrane potential ΔΨm was evaluated
by JC-1 staining to determine whether mitochondrial
dysfunction was involved in the apoptosis. As shown in
Figure 6A, SAMC treated cells led to the dissipation of
ΔΨm as indicated by increasing in green fluorescence
emission. The flow cytometric analysis revealed that sig-
nificant numbers of cells lose ΔΨm after the SAMC
treatment (Figure 6B). Bcl-2 family proteins have been
reported to regulate ΔΨm. The expression of Bcl-2, Bax
Figure 6 Mitochondrial dysfunction and the effect on expression of associative proteins after SAMC treatment. (A) The effect of SAMC
on ΔΨm by JC-1 staining at the dose of 400 μM at 12 and 24 h. The photos were taken under 40× magnifications by a fluorescence microscope.
The intensity of green fluorescence represents the loss of ΔΨm. (B) The loss of ΔΨm analyzed by flow cytometry. (C) MCF-7 and MDA-MB-231
were treated with various concentrations of SAMC for 24 h, Bcl-2 family proteins such as Bcl-2, Bax, Bcl-XL and cytochrome C were analyzed by
the Western blot assay. The experiments were performed in triplicate and values are expressed as mean ± S.D., *p < 0.05 when compared with
control group.
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the results reveal that SAMC treatment suppressed the
expression of Bcl-2 and Bcl-XL, and increased the ex-
pression levels of Bax (Figure 6C). Further experiment
was performed and cytosolic preparations were analyzed
to examine whether the dysfunction of the ΔΨm resulted
in the release of cytochrome c. The experimental results
show that the amount of cytochrome c in the cytosol
was significantly increased. These results suggest that
the disruption of the mitochondrial membrane potential
may be involved in SAMC-induced apoptosis.Discussion
Current conventional chemotherapy treatments are very
expensive, toxic, and less effective in the majority cancer
treatment. Plant-derived active components have been
gaining more attention for their anticancer activities,
over the last 25 years, approximately 63% of anticancer
drugs introduced are natural products or can be traced
back to a natural product source [34]. Garlic (Allium
sativum), a member of the lily family, is widely cultivated
and consumed worldwide. Many different health benefits
have been ascribed to garlic for its diverse organosulfur
Figure 7 The possible mechanisms of SAMC-induced cell cycle
arrest and apoptosis in breast cancer cell lines MCF-7 and
MDA-MB-231.
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have been reported by numerous epidemiological, clin-
ical, and preclinical studies. At the same time, the use of
garlic as the complementary and alternative medicine
(CAM) by patients who are diagnosed with cancers is in-
creasing. This phenomenon is without exception in the
treatment of breast cancer.
In this study, we explored the molecular mechanisms
by which SAMC induced cell apoptosis and cell death in
breast cancer cell lines MCF-7 and MDA-MB-231. Our
data demonstrate that SAMC exerted its inhibitory ef-
fects on cell proliferation of both ER positive and ER
negative breast cancer cell lines MCF-7 and MDA-MB-
231 by inducing G0/G1 cell cycle arrest, and simultan-
eously induced apoptosis in these two cell lines in a
dose-and time-dependent manner.
It is well known that p53 plays a critical role in the in-
duction of apoptosis, autophagy and cell cycle arrest.
The CDKs and cyclin complexes were believed to influ-
ence the progression of cell cycle and its inactivation
leads to cell cycle arrest; therefore, induction of cell
cycle arrest has been appreciated as a target for the
management of cancer [25-27]. This study revealed that
SAMC enforced cell cycle arrest in the G0/G1 phase by
activation of p53 and its key downstream target p21.
Meanwhile, the expression levels of cyclin proteins such
as cyclin D1 and cyclin E1 were down-regulated by
SAMC. It is believed that p53 stimulated the transcrip-
tion of different genes including p21, which is one of the
cyclin-dependent kinase inhibitors. The induction of p21
resulted in CDK inhibition and cell cycle arrest, prevent-
ing the replication of damaged DNA [25]. It is likely that
SAMC induced cell cycle arrest by p53 pathways as well
as other signaling mechanisms since cell cycle check-
points could be regulated by multi-factors. A variety of
diseases including cancer can be caused by abnormalities
in cell death control. Proteolytic enzymes such as cas-
pases are important effective molecules in apoptosis.
Activation of caspases in response to anticancer chemo-
therapy can be initiated through activation of the extrinsic
(receptor) pathway or at the mitochondria by stimulating
the intrinsic pathway [35]. The intrinsic pathway involves
release of pro-apoptotic molecules from mitochondria to
the cytosol such as cytochrome c that trigger the caspase
cascade [36]. The main regulators of the intrinsic pathway
are members of the Bcl-2 family proteins [37]. The extrin-
sic pathway relies on ligand activated recruitment of
adaptor proteins by the death receptor and subsequent ac-
tivation of caspase-8 [38].
Our investigation indicated that SAMC induced apop-
tosis of human cancer cell lines MCF-7 and MDA-MB-
231 in a caspase-dependent way through extrinsic and
intrinsic pathways (Figure 7). The mitochondrial func-
tion is regulated by Bcl-2 family proteins, which isthought to be key pathway for apoptosis. The mitochon-
drial dysfunction will lead to the reduction of mitochon-
drial membrane potential and generation of reactive
oxygen species (ROS), which play an important role in
cell apoptosis. Our results suggest that the Bcl-2 expres-
sion was decreased while the Bax expression was signifi-
cantly increased, which was associated with the loss of
ΔΨm and release of cytochrome c. In addition, the
SAMC treatment of human breast cancer cell lines
MCF-7 and MDA-MB-231 resulted in the activation of
caspase-9 and caspas-3/7 as well as the increase of
PARP, which lead to the intrinsic apoptosis. The extrin-
sic pathway of the apoptosis of human cancer cell lines
MCF-7 and MDA-MB-231 after the SAMC treatment
was revealed by the increase of FADD (fas) and the acti-
vation of caspase-8.
E-cadherin-mediated cell-cell adhesions limit cell mo-
tility and establish apical-basal polarity. Alterations of E-
cadherin expression and disassembly of E-cadherin ad-
hesion are consistently associated with the progression
of carcinoma from a non-invasive to an invasive, meta-
static phenotype [39]. In breast cancer, ER-positive tu-
mors have been demonstrated to express normal
amounts of the E-cadherin protein, and loss of ER and
E-cadherin genes has been linked to disease progression
of invasive breast carcinomas [40]. In this study, our re-
sults indicate that SAMC could inhibit the cell migration
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both of ER-positive and ER-negative breast cancer cells,
which could be a huge advantage in the chemopreven-
tion and chemotherapy of breast cancer.
Conclusion
This study elucidated the cellular mechanisms of SAMC
as an anticancer agent for both ER-positive and ER-
negative breast cancer cell lines MCF-7 and MDA-MB-
231. Our results indicate that the inhibitory effect of
SAMC against the breast cancer cell lines MCF-7 and
MDA-MB-231 involved cell cycle arrest in the G0/G1
phase. Cell apoptosis was mediated by caspase activation
and mitochondrial dysfunction. These findings support
the continued investigation of SAMC as an alternative
agent in the chemoprevention and chemotherapy for
both ER-positive and ER-negative human breast cancer.
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